Forsta AP Fonden Sells 3,900 Shares of Edwards Lifesciences Co. (NYSE:EW)

Forsta AP Fonden lowered its position in Edwards Lifesciences Co. (NYSE:EWFree Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 130,100 shares of the medical research company’s stock after selling 3,900 shares during the quarter. Forsta AP Fonden’s holdings in Edwards Lifesciences were worth $9,631,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in EW. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth about $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the period. Peoples Bank KS bought a new stake in Edwards Lifesciences during the 3rd quarter valued at about $40,000. Finally, Roble Belko & Company Inc bought a new position in Edwards Lifesciences in the 4th quarter worth about $46,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 in the last 90 days. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on EW shares. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Barclays boosted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. Citigroup lifted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Piper Sandler lowered their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $79.19.

View Our Latest Analysis on Edwards Lifesciences

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $73.15 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $43.14 billion, a P/E ratio of 10.56, a PEG ratio of 3.54 and a beta of 1.11. The business has a 50 day simple moving average of $72.40 and a two-hundred day simple moving average of $70.07.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.